CRISPR Therapeutics AG
CRSP
株式のランク
#3562
CRISPR Therapeutics AG (CRSP) is a biotechnology firm dedicated to pioneering... CRISPR Therapeutics AG (CRSP) is a biotechnology firm dedicated to pioneering gene-based medicines for severe diseases. The company achieves this through its exclusive Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9) technology, which enables precise and targeted alterations to an organism's genetic code. Its extensive pipeline includes therapeutic candidates spanning multiple medical areas, such as blood disorders (hemoglobinopathies), various cancers (oncology), regenerative medicine, and rare conditions. The company's flagship investigational therapy is CTX001, an ex vivo CRISPR gene-edited treatment. This therapy aims to benefit patients with transfusion-dependent beta-thalassemia or severe sickle cell disease by modifying their own hematopoietic stem cells to markedly boost the production of fetal hemoglobin within red blood cells. CRISPR Therapeutics is also advancing several other genetically engineered allogeneic (donor-sourced) CAR-T investigational therapies: CTX110, designed to combat cluster of differentiation 19-positive malignancies; CTX120, which targets B-cell maturation antigen for multiple myeloma that has relapsed or proven resistant to previous treatments; and CTX130, focused on Cluster of Differentiation 70 for a spectrum of solid tumors and blood cancers. Furthermore, the company is developing VCTX210, an immune-evasive, gene-edited stem cell-derived product candidate for treating type 1 diabetes. It is also pursuing various in vivo gene-editing initiatives aimed at addressing disorders affecting the liver, lungs, muscles, and central nervous system. The company has forged strategic alliances with significant partners, including Bayer Healthcare LLC, Vertex Pharmaceuticals Incorporated, ViaCyte, Inc., Nkarta, Inc., and Capsida Biotherapeutics. CRISPR Therapeutics AG was established in 2013 and maintains its headquarters in Zug, Switzerland.
株価
$50.26
時価総額
$4.86B
変化（1日）
0.44%
変化（1年）
-32.05%
国
CH
取引 CRISPR Therapeutics AG (CRSP)
カテゴリー
Healthcare
CRISPR Therapeutics AG（CRSP）のP/S比率
October 2026 時点のP/S比率 TTM: 362.60
CRISPR Therapeutics AG の最新の財務報告および株価によると、現在のP/S比率（TTM）は 362.60 です。2023 年末時点でのP/S比率は 13.36 でした。
CRISPR Therapeutics AG の P/S 比率の履歴（2014 ～ 2026）
各年末時点のP/S比率
| 年 | P/S比率 | 変化 |
|---|---|---|
| 2026 (TTM) | 362.60 | 282.20% |
| 2024 | 94.87 | 610.10% |
| 2023 | 13.36 | -99.82% |
| 2022 | 7.25K | 114,897.22% |
| 2021 | 6.30 | -99.97% |
| 2020 | 18.60K | 162,458.37% |
| 2019 | 11.44 | -97.39% |
| 2018 | 438.61 | 1,815.76% |
| 2017 | 22.89 | -52.39% |
| 2016 | 48.09 | -97.12% |
| 2015 | 1.67K | 0.00% |
| 2014 | 0.00 | 0.00% |
同業他社のP/S比率
| 企業 | P/S比率 | P/S比率の差 | 国 |
|---|---|---|---|
| 10.02 | -97.24% |
US
|
|
| 40.55 | -88.82% |
US
|
|
| 3.96 | -98.91% |
AU
|
|
| - | - |
CH
|
|
| 10.15 | -97.20% |
NL
|
